Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):513-515. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2023.0044

View: 611 Download: 25

Letter to the Editor

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 686 Download: 37

Review

The role of different viral biomarkers on the management of chronic hepatitis B

Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):263-276. Published online January 19, 2023

DOI: https://doi.org/10.3350/cmh.2022.0448

View: 1360 Download: 171 Citation: 1

Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(2):252-262. Published online March 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0099

View: 1143 Download: 128

Correspondence

Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”

Won Sohn, Yong-Han Paik

Clin Mol Hepatol. 2023;29(1):182-184. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0411

View: 1260 Download: 28

Original Article

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0172

View: 2400 Download: 179 Citations: 6

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2022;28(4):890-911. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0087

View: 2883 Download: 149 Citations: 9

Review

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee

Clin Mol Hepatol. 2022;28(3):351-361. Published online November 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0281

View: 3193 Download: 200 Citations: 8

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 6822 Download: 463 Citations: 20

Original Article

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

DOI: https://doi.org/10.3350/cmh.2021.0314

View: 3172 Download: 240 Citations: 8

Letter to the Editor

A dilemma that probably would never resolve

Ravi Thanage, Shubham Jain, Sanjay Chandnani, Pravin Rathi

Clin Mol Hepatol. 2021;27(1):219-220. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0274

View: 2392 Download: 68

Editorial

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0099

View: 3913 Download: 103 Citation: 1

Original Article

The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer?

Sujata Lall, Pragya Agarwala, Guresh Kumar, Manoj Kumar Sharma, Ekta Gupta

Clin Mol Hepatol. 2020;26(2):187-195. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2019.0060

View: 8026 Download: 272 Citations: 10

Editorial

Should physicians go out of the way to differentiate between acute hepatitis B and acute exacerbation of chronic hepatitis B?

Hyun Woong Lee

Clin Mol Hepatol. 2020;26(2):180-182. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0045

View: 3230 Download: 98

Review

Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C

Seong Kyun Na, Byung-Cheol Song

Clin Mol Hepatol. 2019;25(3):234-244. Published online January 21, 2019

DOI: https://doi.org/10.3350/cmh.2018.0108

View: 7165 Download: 237 Citations: 21

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2019;25(2):168-171. Published online February 11, 2019

DOI: https://doi.org/10.3350/cmh.2018.1014

View: 5132 Download: 179 Citations: 4

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2019;25(2):93-159. Published online June 12, 2019

DOI: https://doi.org/10.3350/cmh.2019.1002

View: 21682 Download: 612 Citations: 126

Original Article

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

Shinya Sato, Kei Moriya, Masanori Furukawa, Soichiro Saikawa, Tadashi Namisaki, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Naotaka Shimozato, Yasuhiko Sawada, Kenichiro Seki, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Yasushi Okura, Junichi Yamao, Hitoshi Yoshiji

Clin Mol Hepatol. 2019;25(1):65-73. Published online February 25, 2019

DOI: https://doi.org/10.3350/cmh.2018.0070

View: 7118 Download: 131 Citations: 3

Case Report

Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B

Hyeji Kim, Jung Hyun Kwon, Yong Hee Kim, Soon Woo Nam, Jong Yul Lee, Jeong Won Jang

Clin Mol Hepatol. 2018;24(4):430-435. Published online November 27, 2017

DOI: https://doi.org/10.3350/cmh.2017.0016

View: 7057 Download: 215 Citations: 2

Original Article

Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases

San Juan López Cristina, Casado Martín Marta, González Sánchez Mercedes, Porcel Martín Almudena, Hernández Martínez Álvaro, Vega Sáenz Jose Luis, Parrón Carreño Tesifón

Clin Mol Hepatol. 2018;24(4):384-391. Published online July 4, 2018

DOI: https://doi.org/10.3350/cmh.2018.0004

View: 6805 Download: 191 Citations: 9

Review

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

Soon Young Ko, Won Hyeok Choe

Clin Mol Hepatol. 2018;24(4):351-357. Published online March 16, 2018

DOI: https://doi.org/10.3350/cmh.2017.0063

View: 8668 Download: 340 Citation: 1

Editorial

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

Jong Eun Yeon

Clin Mol Hepatol. 2018;24(3):294-296. Published online September 11, 2018

DOI: https://doi.org/10.3350/cmh.2018.1009

View: 5763 Download: 78 Citations: 2

Review

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

Clin Mol Hepatol. 2018;24(3):169-229. Published online August 10, 2018

DOI: https://doi.org/10.3350/cmh.2018.1004

View: 13024 Download: 214 Citations: 23

Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend

Grace Lai-Hung Wong

Clin Mol Hepatol. 2018;24(2):108-113. Published online January 22, 2018

DOI: https://doi.org/10.3350/cmh.2017.0068

View: 11379 Download: 488 Citations: 34

Editorial

Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?

Joon Yeul Nam, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(4):311-313. Published online December 4, 2017

DOI: https://doi.org/10.3350/cmh.2017.0069

View: 5271 Download: 137

Use of sofosbuvir in chronic kidney disease: Is it necessary?

Tae Seop Lim, Sang Hoon Ahn

Clin Mol Hepatol. 2017;23(4):308-310. Published online September 26, 2017

DOI: https://doi.org/10.3350/cmh.2017.0109

View: 5112 Download: 118 Citations: 6

Original Article

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir

Hee-Jeong Jeon, Seok Won Jung, Neung Hwa Park, Yujin Yang, Jin-Hee Noh, Jae-Sung Ahn, Hyung Rae Kim, Jae Ho Lee, Jung Woo Shin

Clin Mol Hepatol. 2017;23(3):230-238. Published online June 30, 2017

DOI: https://doi.org/10.3350/cmh.2017.0003

View: 8437 Download: 160 Citations: 13

Editorial

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?

Yun Bin Lee, Jeong-Hoon Lee

Clin Mol Hepatol. 2017;23(3):219-221. Published online September 19, 2017

DOI: https://doi.org/10.3350/cmh.2017.0045

View: 6917 Download: 149 Citations: 2

Original Article

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B

Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin-Ho Jung, Yong-Han Paik

Clin Mol Hepatol. 2017;23(2):170-178. Published online May 16, 2017

DOI: https://doi.org/10.3350/cmh.2016.0086

View: 8310 Download: 206 Citations: 34

Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B

Hee Yeon Seo, Han Ah Lee, Soon Young Ko, Joon Ho Wang, Jeong Han Kim, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2017;23(2):154-159. Published online May 8, 2017

DOI: https://doi.org/10.3350/cmh.2016.0067

View: 6690 Download: 170 Citations: 7

1 | 2 | 3 | 4 | 5 |

Viewed By 4166	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 3570	Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Viewed By 2833	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2789	Recent updates on the management of autoimmune hepatitis
Viewed By 2710	Identification of high-risk subjects in nonalcoholic fatty liver disease

Cited By 99	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 42	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Search